Mankind Pharma Ltd
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
- Market Cap ₹ 1,00,985 Cr.
- Current Price ₹ 2,447
- High / Low ₹ 3,055 / 2,115
- Stock P/E 53.4
- Book Value ₹ 347
- Dividend Yield 0.04 %
- ROCE 16.0 %
- ROE 14.7 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 7.04 times its book value
- Debtor days have increased from 33.4 to 46.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 3,334 | 5,865 | 6,214 | 7,782 | 8,749 | 10,260 | 12,207 | 12,925 | |
| 2,748 | 4,427 | 4,565 | 5,791 | 6,848 | 7,743 | 9,182 | 9,729 | |
| Operating Profit | 586 | 1,438 | 1,649 | 1,991 | 1,902 | 2,517 | 3,026 | 3,196 | 
| OPM % | 18% | 25% | 27% | 26% | 22% | 25% | 25% | 25% | 
| 76 | 122 | 183 | 210 | 141 | 295 | 548 | 531 | |
| Interest | 2 | 23 | 21 | 60 | 46 | 34 | 432 | 589 | 
| Depreciation | 39 | 99 | 119 | 167 | 326 | 378 | 621 | 742 | 
| Profit before tax | 621 | 1,438 | 1,692 | 1,975 | 1,671 | 2,399 | 2,521 | 2,396 | 
| Tax % | 29% | 27% | 24% | 26% | 22% | 19% | 20% | |
| 445 | 1,056 | 1,293 | 1,453 | 1,310 | 1,942 | 2,011 | 1,913 | |
| EPS in Rs | 219.33 | 25.72 | 31.59 | 35.78 | 32.00 | 47.75 | 48.26 | 46.35 | 
| Dividend Payout % | 0% | 0% | 24% | 0% | 0% | 0% | 0% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% | 
| 5 Years: | 16% | 
| 3 Years: | 16% | 
| TTM: | 22% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% | 
| 5 Years: | 12% | 
| 3 Years: | 8% | 
| TTM: | -3% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | % | 
| 5 Years: | % | 
| 3 Years: | % | 
| 1 Year: | -8% | 
| Return on Equity | |
|---|---|
| 10 Years: | % | 
| 5 Years: | 20% | 
| 3 Years: | 18% | 
| Last Year: | 15% | 
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 40 | 40 | 40 | 40 | 40 | 41 | 
| Reserves | 2,035 | 3,445 | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 
| 0 | 131 | 241 | 873 | 170 | 207 | 8,511 | |
| 968 | 1,449 | 1,397 | 2,080 | 2,080 | 2,313 | 4,808 | |
| Total Liabilities | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 
| 316 | 1,600 | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | |
| CWIP | 47 | 317 | 372 | 701 | 550 | 282 | 826 | 
| Investments | 959 | 829 | 1,512 | 1,109 | 1,346 | 2,568 | 2,042 | 
| 1,700 | 2,319 | 2,811 | 3,709 | 3,538 | 4,488 | 5,780 | |
| Total Assets | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 | ||
| -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 | ||
| -531 | -8 | 605 | -740 | 5 | 10,233 | ||
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 | 
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 33 | 19 | 18 | 24 | 30 | 46 | 
| Inventory Days | 166 | 175 | 243 | 265 | 188 | 180 | 219 | 
| Days Payable | 71 | 145 | 137 | 162 | 126 | 90 | 119 | 
| Cash Conversion Cycle | 117 | 63 | 125 | 121 | 85 | 120 | 146 | 
| Working Capital Days | 56 | 30 | 32 | 24 | 39 | 53 | -28 | 
| ROCE % | 37% | 32% | 22% | 26% | 16% | 
Documents
Announcements
- 
        
          Intimation Regarding ESG Rating
          
            1d - CFC Finlease assigned ESG score 69 to Mankind Pharma on October 29, 2025.
- 
        
          Announcement under Regulation 30 (LODR)-Credit Rating
          
            1d - CRISIL withdrew rating for ₹1,250cr bank facilities; reaffirmed NCDs ₹400cr and ₹4,600cr; CP limit reduced to ₹1,500cr.
- 
        
          Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
          
            1d - Investor conference call on Nov 6, 2025 at 06:00 PM IST for Q2 & H1 FY26 results.
- 
        
          Board Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended On September 30, 2025
          
            27 Oct - Board meeting on Nov 6, 2025 to approve Q2/HY Sep 30, 2025 results; trading window closed till Nov 8, 2025.
- 
        
          Announcement under Regulation 30 (LODR)-Updates on Acquisition
          
            10 Oct - Mankind Pharma acquires Women Health Rx portfolio from BSV for ₹797 Crore via slump sale; 50% on closing.
Annual reports
Concalls
- 
      Aug 2025Transcript PPT REC
- 
      May 2025Transcript PPT
- 
      Jan 2025Transcript PPT
- 
      Nov 2024Transcript PPT
- 
      Sep 2024TranscriptNotesPPT
- 
      Aug 2024TranscriptNotesPPT
- 
      Aug 2024Transcript PPT
- 
      Aug 2024Transcript PPT
- 
      Jul 2024TranscriptNotesPPT
- 
      May 2024Transcript PPT
- 
      Feb 2024Transcript PPT
- 
      Jan 2024TranscriptNotesPPT
- 
      Nov 2023Transcript PPT
- 
      Aug 2023Transcript PPT
- 
      Jun 2023Transcript PPT
Leadership[1]
- 1 Rank in Prescriptions over the last 5 yrs.
- Youngest in the Top 5 of the IPM
- 4 By value in the IPM
- 4 Consumer Healthcare brands Market ranked
1 in their categories